Neuroprotective role of dopamine agonists: Evidence from animal models and clinical studies

Neurologist

Volumn 17, Issue 6 SUPPL., 2011, Pages

  Herrero, Maria Trinidad ^a   Pagonabarraga, Javier ^b   Linazasoro, Gurutz ^c  

^a UNIVERSITY OF MURCIA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c Fundacion Inbiomed   (Spain)

Author keywords

clinical trials; neuroprotection; neurorescue; Parkinson disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CALCIUM CHANNEL; CASPASE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GLYCOGEN SYNTHASE KINASE 3; INTERLEUKIN 1; INTERLEUKIN 6; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; OXIDOPAMINE; PERGOLIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POTASSIUM; PRAMIPEXOLE; PROTEIN BCL 2; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; ROPINIROLE; ROTIGOTINE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; AUTOOXIDATION; AUTOPHAGY; CALCIUM CELL LEVEL; CELL DAMAGE; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CELL REGENERATION; COGNITIVE DEFECT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEGENERATIVE DISEASE; DIAGNOSTIC ERROR; DISEASE COURSE; DNA DAMAGE; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME STABILITY; FOLLOW UP; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPID PEROXIDATION; MITOCHONDRION; MORBIDITY; NERVE CELL DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PALLIATIVE THERAPY; PARKINSON DISEASE; PHOSPHORYLATION; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY CHAIN; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TEMPORAL CORTEX; UPREGULATION;

ANIMALS; ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINE AGONISTS; HUMANS; LEVODOPA; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 80455174241     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e31823968fc     Document Type: Article

References (136)

1. Hindle JV. Ageing, neurodegeneration and Parkinson's Disease Ageing, neurodegeneration and Parkiknson's disease. Age Ageing. 2010;39:156-161.
2. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197-211.
3. Graeber MB, Moran LB. Mechanisms of cell death in neurodegenerative diseases: Fashion, fiction, and facts. Brain Pathol. 2002;12:385-390.
4. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: A target for neuroprotection? Lancet Neurol. 2009;8:382-397.
5. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiology Dis. 2010;37:510-518.
6. Bandopadhyay R, De Belleroche J. Pathogenesis of Parkinson's disease: Emerging role of molecular chaperones. Trends Mol Med. 2009;16:27-36.
7. Meissner WG, Frasier M, Gasser T, et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov. 2011;10:377-393.
8. Postuma RB, Gagnon JF, Montplaisir J. Clinical prediction of Parkinson's disease: Planning for the age of neuroprotection. J Neurol Neurosurg Psychiatry. 2010. [Epub ahead of print].
9. Levi-Montalcini R. The nerve growth factor 35 five years later. Science. 1987;237:1154-1162.
10. Hawkes CH. The prodromal phase of sporadic Parkinson's disease: Does it exist and if so how long is it? Mov Disord. 2008;23:101-106.
11. Schapira AHV, Olanow CW. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann Neurol. 2003;53(Suppl 3):S149-S157.
12. Schapira AHV. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson's disease. Neurology. 2009;72(Suppl 2):S44-S50.
13. Linazasoro G. A global view of Parkinson's disease pathogenesis: Implications for natural history and neuroprotection. Parkinsonism Relat Disord. 2009;15:401-405.
14. Olanow CW, Kordower JH, Lang AE, et al. Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Ann Neurol. 2009;66:591-596.
15. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003;54:403-414.
16. Chu Y, Kordower JH. Lewy body pathology in fetal grafts. Ann N Y Acad Sci. 2010;1184:55-67.
17. Ramaswamy S, Soderstrom KE, Kordower JH. Trophic factors therapy in Parkinson's disease. Prog Brain Res. 2009;175: 201-216.
18. Bjorklund T, Kordower JH. Gene therapy for Parkinson's disease. Mov Disord. 2010;25(Suppl 1):S161-S173.
19. Löhle M, Reichmann H. Clinical neuroprotection in Parkinson's disease: Still waiting for the breakthrough. J Neurol Sci. 2010;289(1-2):104- 114.
20. George JL, Mok S, Moses D, et al. Targeting the progression of Parkinson's disease. Current Neuropharmacol. 2009;7:9-36.
21. Gupta A, Dawson VL, Dawson TM. What causes cell death in Parkinson's disease? Ann Neurol. 2008;64(Suppl):S3-S15.
22. Olanow CW, Rascol O, Hauser R, et al. ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361:1268-1278.
23. Halliday GM, McCann H. The progression of pathology in Parkinson's disease. Ann N Y Acad Sci. 2009;1184:188-195.
24. Agid Y. Levodopa: Is toxicity a myth? Neurology. 1998;50: 858-863.
25. Albrecht S, Buerger E. Potential neuroprotection mechanisms in PD: Focus on dopamine agonist pramipexole. Curr Med Res Opin. 2009;25:2977-2987.
26. Alegre-Abarrategui J, Wade-Martins R. Parkinson disease, LRRK2 and the endocytic-autophagic pathway. Autophagy. 2009;5:1208-1210.
27. Allain H, Bentue-Ferrer D, Akwa Y. Disease-modifying drugs and Parkinson's disease. Prog Neurobiol. 2008;84:25-39.
28. Amer DA, Irvine GB, El-Agnaf OM. Inhibitors of alphasynuclein oligomerization and toxicity: A future therapeutic strategy for Parkinson's disease and related disorders. Exp Brain Res. 2006;173:223-233.
29. Asanuma M, Miyazaki I. Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease. Curr Pharm Des. 2008;14:1428-1434.
30. Bousquet M, Gibrat C, Saint-Pierre M, et al. Modulation of brainderived neurotrophic factor as potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1401-1408.
31. Sulzer D. Multiple hit hypothesis for dopamine neuron loss in Parkinson's disease. Trends Neurosci. 2007;30:244-250.
32. Nuytemans K, Theuns J, Cruts M, et al. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update. Hum Mutat. 2010;31:763-780.
33. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. Neuron. 2010;66:646-661.
34. Westerlund M, Hoffer B, Olson L. Parkinson's disease: Exit toxins, enter genetics. Prog Neurobiol. 2010;90:146-156.
35. Cavalli A, Bolognesi ML, Minarini A, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem. 2008;51:7308-7312.
36. Vives-Bauza C, de Vries RL, Tocilescu MA, et al. Is there a pathogenic role for mitochondria in Parkinson's disease? Parkinsonism Relat Disord. 2009;15(Suppl3):S241-S244.
37. Yang L, Calingasan NY, Wille EJ, et al. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem. 2009;109:1427-1439.
38. Beal MF. Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism Relat Disord. 2009;15 (Suppl 3):S189-S194.
39. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res. 2009;196:168-179.
40. Betarbet R, Sherer TB, Greenamyre JT. Ubiquitin-proteasome system and Parkinson's diseases. Exp Neurol. 2005;191(Suppl 1):S17-S27.
41. Bisaglia M, Soriano ME, Arduini I, et al. Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: Implications for mitochondrial dysfunction in Parkinson disease. Biochem Biophys Acta. 2010;1802: 699-706.
42. Zhu W, Li X, Xie W, et al. Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration. Neurobiol Dis. 2010;37:307-313.
43. Ghosh B, Antonio T, Reith ME, et al. Discovery of 4-(4-(2-((5- Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl) piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: In vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease. J Med Chem. 2010;53:2114-2125.
44. Weinreb O, Amit T, Bar-Am O, et al. Rasagiline: A novel antiparkinsonian monoamine oxidase-b inhibitor with neuroprotective activity. Prog Neurobiol. 2010;92:330-344.
45. Pfeiffer RF. Parkinson disease: calcium channel blockers and Parkinson disease. Nat Rev Neurol. 2010;6:188-189.
46. Surmeier DJ, Guzman JN, Sanchez-Padilla J. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease. Cell Calcium. 2010;47:175-182.
47. Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002;8:271-276.
48. Putcha P, Danzer KM, Kranich LR, et al. Brain-permeable smallmolecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. Pharmacol Exp Ther. 2010;332:849-857.
49. Qiao L, Hamamichi S, Caldwell KA, et al. Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain. 2008;1:17.
50. Masliah E, Rockenstein E, Adame A, et al. Effects of alphasynuclein immunization in a mouse model of Parkinson's disease. Neuron. 2005;46:857-868.
51. Koga H, Cuervo AM. Chaperone-mediated autophagy dysfunction in the pathogenesis of neurodegeneration. Neurobiol Dis. 2010. [Epub ahead of print].
52. Wong E, Cuervo AM. Autophagy gone awry in neurodegenerative diseases. Nat Neurosci. 2010;13:805-811.
53. Cheung ZH, Ip NY. Autophagy deregulation in neurodegenerative diseases-recent advances and future perspectives. J Neurochem. 2011;118:317-325.
54. Matsuda N, Tanaka K. Does impairment of the ubiquitinproteasome system or the autophagy-lysosome pathway predispose individuals to neurodegenerative disorders such as Parkinson's disease? J Alzheimer Dis. 2010;19:1-9.
55. Snyder H, Wolozin B. Pathological proteins in Parkinson's disease: Focus on the proteasome. J Mol Neurosci. 2004;24: 425-442.
56. Yue Z. LRRK2 in Parkinson's disease: In vivo models and approaches for understanding pathogenic roles. FEBS J. 2009;276:6445-6454.
57. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-257.
58. Orrenius S, Gogvadze V, Zhivotovsky B. Mitochondrial oxidative stress: Implications for cell death. Annu Rev Pharmacol Toxicol. 2007;47:143-183.
59. Zhivotovsky B, Orrenius S. Cell death mechanisms: cross-talk and role in disease. Exp Cell Res. 2010;316:1374-1383.
60. De Castro IP, Martins LM, Tufi R. Mitochondrial quality control and neurological disease: An emerging connection. Exprt Rev Mol Med. 2010;19:e12.
61. Glass CK, Saijo K, Winner B, et al. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140: 918-934.
62. Barcia C, Sánchez Bahillo A, Fernández-Villalba E, et al. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia. 2004; 46:402-409.
63. Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis. Neurology. 2010;74: 995-1002.
64. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Ab42 independently of cyclooxygenase activity. Nature. 2001;414:212-216.
65. Tsuji T, Asanuma M, Miyazaki I, et al. Reduction of nuclear peroxisome proliferator-activated receptor gamma expression in methamphetamine-induced neurotoxicity and neuroprotective effects of ibuprofen. Neurochem Res. 2009;34:764-774.
66. Jiang C, Ting AT, Seed B. PPAR-c agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
67. Frim DM, Uhler TA, Galpern WR, et al. Implanted fibroblast genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci. 1995;15:7810-7820.
68. Choi-Lundberg DL, Lin Q, Chang YN, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science. 1997;275:838-841.
69. Rosenblad C, Kirik D, Devaux B, et al. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci. 1999;11:1554-1566.
70. Ramaswamy S, Kordower JH. Are growth factors the answer? Parkinsonism Relat Disord. 2009;15S3:S176-S180.
71. Schapira AHV. Dopamine agonists and neuroprotection in Parkinson's disease. Eur J Neurol. 2002;9(Suppl 3):7-14.
72. Felten DL, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats. Neurobiol Aging. 1992;13:339-351.
73. Hubble JP. Pre-clinical studies of pramipexole: clinical relevance. Eur J Neurol. 2000;7(Suppl 1):15-20.
74. Cassarino DS, Fall CP, Smith TS, et al. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem. 1998;71:295-301.
75. Takata K, Kitamura Y, Kakimura J, et al. Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole. Brain Res. 2000;872:236-241.
76. Ling ZD, Robie HC, Tong CW, et al. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. J Pharmacol Exp Ther. 1999; 289:202-10.
77. Grunblatt E, Mandel S, Maor G, et al. Effects of R- and Sapomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J Neurochem. 2001;77:146-156.
78. Gassen M, Gross A, MB Youdim. Apomorphine, a dopamine receptor agonist with remarkable antioxidant and cytoprotective properties. Adv Neurol. 1999;80:297-302.
79. May LT, Leach K, Sexton PM, et al. Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol. 2007; 47:1-51.
80. Strange PG. Mechanisms underlying agonist efficacy. Biochem Soc Trans. 2007;35(Pt4):733-736.
81. Ohta K, Kuno S, Inoue S, et al. The effect of dopamine agonists: The expression of GDNF, NGF, and BDNF in cultured mouse astrocytes. J Neurol Sci. 2010;291(1-2):12-16.
82. Grunblatt E, Mandel S, Gassen M, et al. Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6- hydroxydopamine induced neurotoxicity. J Neural Transm Suppl. 1999;55:57-70.
83. Youdim MB, Gassen M, Gross A, et al. Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine. J Neural Transm Suppl. 2000;58:83-96.
84. Vaglini F, Pardini C, Viaggi C, et al. Apomorphine offers new insight into dopaminergic neuron vulnerability in mesencephalic cultures. Neuropharmacology. 2008;55:737-742.
85. Gassen M, Gross A, Youdim MB. Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov Disord. 1998;13:661-667.
86. Battaglia G, Busceti CL, Cuomo L, et al. Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice. Neuropharmacology. 2002a;42:367-373.
87. Battaglia G, Gesi M, Lenzi P, et al. Morphological and biochemical evidence that apomorphine rescues striatal dopamine terminals and prevents methamphetamine toxicity. Ann N Y Acad Sci. 2002b;965:254-266.
88. Ohta M, Mizuta I, Ohta K, et al. Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun. 2000;272:18-22.
89. Dos Santos El-Bachá R, Daval J, Koziel V, et al. Toxic effects of apomorphine on rat cultured neurons and glial C6 cells, and protection with antioxidants. Biochem Pharmacol. 2001;61: 73-85.
90. Pardini C, Vaglini F, Galimberti S, et al. Dose-dependent induction of apoptosis by R-apomorphine in CHO-K1 cell line in culture. Neuropharmacology. 2003;45:182-189.
91. Kyriazis M. Neuroprotective, anti-apoptotic effects of apomorphine. J Anti Aging Med. 2003;6:21-28.
92. Finotti N, Castagna L, Moretti A, et al. Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment. Pharmacol Res. 2000;42:287-291.
93. Marvanova M, Nichols CD. Identification of neuroprotective compounds of caenorhabditis elegans dopaminergic neurons against 6-OHDA. J Mol Neurosci. 2007;31:127-137.
94. Ohta K, Fujinami A, Kuno S, et al. Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture. Pharmacology. 2004; 71:162-168.
95. Him JL, Kim KM, Kim SW, et al. Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signalling: Novel cytoprotective mechanism against oxidative damage. Pharmacol Res. 2009;57: 325-331.
96. Lim JH, Kim SS, Boo DH, et al. Protective effect of bromocriptine against BH4-induced Cath.a cell death involving up-regulation of antioxidant enzymes. Neurosci Lett. 2009;451: 185-189.
97. Nair VD, Olanow CW, Sealfon SC. Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J. 2003;373:25-32.
98. Nair VD, Olanow CW. Differential modulation of Akt/ glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses. Biol Chem. 2008;283: 15469-15478.
99. Chen S, Zhang X, Yang D, et al. D2/D3 receptor agonist ropirinole protects dopaminergic cell lines against rotenoneinduced apoptosis through inhibition of caspase- and JNKdependent pathways. FEBS Lett. 2008;582:603-610.
100. Micale V, Incognito T, Ignoto A, et al. Dopaminergic drugs may counteract behavioral and biochemical changes induced by models of brain injury. Eur Neuropsychopharmacol. 2006;16: 195-203.
101. Iida M, Miyazaki I, Tanaka K, et al. Dopamine D2 receptormediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 1999;838(1-2):51-59.
102. Tanaka K, Miyazaki I, Fujita N, et al. Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist. Neurochem Res. 2001;26:31-36.
103. Venugopalan DN, Olanow CW. Differential modulation of Akt/ glycogen synthase kinase-3 pathway regulates apoptotic and cytoprotective signaling responses. J Biol Chem. 2008;283: 15469-15478.
104. Parvez S, Winkler-Stuck K, Hertel S, et al. The dopamine-D2- receptor agonist ropinirole dose-dependently blocks the Ca(2+)- triggered permeability transition of mitochondria. Biochim Biophys Acta. 2010;1797(6-7):1245-1250.
105. Linz ZD, Robie HC, Tong CW, et al. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. J Pharmacol Exp Ther. 1999; 289:202-210.
106. Izumi Y, Sawada H, Yamamoto N, et al. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. Eur J Pharmacol. 2007;557(2-3):132-140.
107. Izumi Y, Yamamoto N, Kume T, et al. Regulation of intracellular dopamine levels by dopaminergic drugs: Involvement of vesicular monoamine transporter. Eur J Pharmacol. 2008;582 (1-3):52-61.
108. Sayeed I, Parvez S, Winkler-Stuck K, et al. Patch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2-receptor agonist pramipexole. FASEB J. 2006;20:556-558.
109. Ferrari-Toninelli G, Maccarinelli G, Uberti D, et al. Mitochondria- targeted antioxidant effects of S(+) and R(+) pramipexole. BMC Pharmacol. 2010;10:2.
110. Nair VD, Sealfon SC. Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D2 receptor. J Biol Chem. 2003;278:47053-47061.
111. Presgraves SP, Borwege S, Mj Millan, et al. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. Exp Neurol. 2004;190:157-170.
112. Du F, Li R, Huang Y, et al. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur J Neurosci. 2005;22:2422-2430.
113. Collo G, Zanetti S, Missale C, et al. Dopamine D3 receptorpreferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. Eur J Neurosci. 2008;28:1231-1240.
114. Imamura K, Takeshima T, Nakaso K, et al. Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity. Neuroci Lett. 2008;440:97-102.
115. Iravani MM, Sadeghian M, Leung CC, et al. Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide- induced dopaminergic cell death without affecting the inflammatory response. Exp Neurol. 2008;212:522-531.
116. Li C, Guo Y, Xie W, et al. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease. Neurochem Res. 2010. [Epub ahead of print].
117. Winner B, Desplats P, Hagl C, et al. Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model. Exp Neurol. 2009;219:543-552.
118. Chen JJ, Swope DM, Dashtipour K, et al. Transdermal rotigotine: A clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. Pharmacotherapy. 2009;29: 1452-1467.
119. Jankovic J, Watts RL, Martin W, et al. Transdermal rotigotine: Double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007;64:676-682.
120. Kehr J, Hu XJ, Goiny M, et al. Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation. J Neural Transm. 2007;114:1027-1031.
121. Scheller D, Ullmer C, Berkels R, et al. The in vitro receptor profile of rotigotine: A new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol. 2009;379: 73-86.
122. Scheller D, Stichel-Gunkel C, Lübbert H, et al. Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease. Neurosci Lett. 2008;432:30-34.
123. Scheller D, Chan P, Li Q, et al. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp Neurol. 2007;203:415-422.
124. Ferrari M, Cosentino M, Marino F, et al. Dopaminergic D1-like receptor-dependent inhibition of tyrosine hydroxylase mRNA expression and catecholamine production in human lymphocytes. Biochem Pharmacol. 2004;67:865-873.
125. Lindgren N, Xu ZQ, Herrera-Marschitz M, et al. Dopamine D(2) receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum. Eur J Neurosci. 2001;13: 773-780.
126. Cuervo AM, Wong ES, Martinez-Vicente M. Protein degradation, aggregation, and misfolding. Mov Disord. 2010;25(Suppl 1): S49-S54.
127. Fuente-Fernández R, Schulzer M, Mak E, et al. Trials of neuroprotective therapies for Parkinson's disease. Parkinsonism Relat Disord. 2010;16:365-369.
128. Hauser RA, Zesiewicz TA. Clinical trials aimed at detecting neuroprotection in Parkinson's disease. Neurology. 2006;66 (Suppl 4):S58-S68.
129. Kieburtz K. Issues in neuroprotection clinical trials in Parkinson's disease. Neurology. 2006;66(Suppl 4):S50-S57.
130. Stocchi F, Olanow CW. Neuroprotection in Parkinson's Disease: clinical trials. Ann Neurol. 2003;53(suppl 3):S87-S99.
131. Gasser T. Mendelian forms of Parkinson's disease. Biochem Biophys Acta. 2009;1792:587-596.
132. Schapira AH, Albrecht S, Barone P, et al. Rationale for delayedstart study of pramipexole in Parkinson's disease: The PROUD study. Mov Disord. 2010;25:1627-1632.
133. Lang AE, Obeso JA. Challenges in Parkinson's disease: Restoration of the nigrostriatal system is not enough. Lancet Neurol. 2004;3:309-316.
134. Hirsch EC. How to judge animal models of Parkinson's disease in terms of neuroprotection. J Neural Transm. 2006;70: S255-S260.
135. Olanow CW. Can we achie neuroprotection with currently available anti-parkinsonian interventions? Neurology. 2009;72 (Suppl 2):S59-S64.
136. Schapira AHV. Neurobiology and treatment of Parkinson's disease. Trends Pharmacol Sci. 2008;30:41-47.